
Race Oncology Limited (ASX:RAC) is an ASX-listed clinical stage biopharmaceutical company developing bisantrene, a novel anthracycline chemotherapeutic agent, for the treatment of a variety of cancers. Race Oncology's lead focus is on investigating the anti-cancer, cardio-protective and FTO properties of bisantrene in metastatic breast cancer, with a view to improving therapeutic outcomes and heart health for patients with cancer. Race Oncology is also pursuing increased anti-cancer / FTO benefits of bisantrene combined with current standard of care therapies in acute myeloid leukaemia (AML).